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Abstract
Nanoparticle (NP) size has been shown to signiﬁcantly affect the biodistribution of targeted and non-targeted NPs in an organ speciﬁc
manner. Herein we have developed NPs from carboxy-terminated poly(D,L-lactide–co–glycolide)–block–poly(ethylene glycol)
(PLGA–b–PEG–COOH) polymer and studied the effects of altering the following formulation parameters on the size of NPs: (1)
polymer concentration, (2) drug loading, (3) water miscibility of solvent, and (4) the ratio of water to solvent. We found that NP mean
volumetric size correlates linearly with polymer concentration for NPs between 70 and 250nm in diameter (linear coefﬁcient ¼ 0.99 for
NPs formulated with solvents studied). NPs with desirable size, drug loading, and polydispersity were conjugated to the A10 RNA
aptamer (Apt) that binds to the prostate speciﬁc membrane antigen (PSMA), and NP and NP-Apt biodistribution was evaluated in a
LNCaP (PSMA+) xenograft mouse model of prostate cancer. The surface functionalization of NPs with the A10 PSMA Apt
signiﬁcantly enhanced delivery of NPs to tumors vs. equivalent NPs lacking the A10 PSMA Apt (a 3.77-fold increase at 24h; NP-Apt
0.83%70.21% vs. NP 0.22%70.07% of injected dose per gram of tissue; mean7SD, n ¼ 4, p ¼ 0:002). The ability to control NP size
together with targeted delivery may result in favorable biodistribution and development of clinically relevant targeted therapies.
r 2006 Elsevier Ltd. All rights reserved.
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1. Introduction
Several decades of biomaterials research have led to a
progressively heightened interest in the use of biodegrad-
able polymeric nanoparticles (NPs) for drug delivery
applications [1–5]. NPs can accumulate in tumors after
systemic administration, and their biodistribution is largely
determined by their physical and biochemical properties,
such as particle size, nature of the polymer and drug, and
surface biochemical properties [6]. The effect of size on NP
biodistribution has been shown to be organ speciﬁc and
non-linear [7]. This is in part due to organ-speciﬁc physical
and physiological barriers that systemically administered
NPs encounter [8]. Studies on liposomes have shown
that splenic sequestration of particles decreases linearly
with decreases in particle size [9,10]. For the liver, the
dependence on size is non-linear. While larger NPs are
sequestered in the liver consistent with the observations in
the spleen, the very small NPs (less than 70nm) can pass
through the sinusoidal fenestrations in the liver and be
entrapped by underlying parenchymal cells [11]. In the case
of bone marrow, larger particles are generally excluded,
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but smaller particles that escape spleen and liver sequestra-
tion can partition more effectively in the bone marrow
depending on their surface characteristics [12]. The effect of
NP size on biodistribution is therefore non-linear and
varies from organ to organ, underscoring the importance
of tuning NP size for each distinct in vivo application.
Recently, we developed  250nm NP-aptamer (NP-Apt)
bioconjugates using poly(D,L-lactide)–block–poly(ethylene
glycol) (PLA–b–PEG) copolymer and the A10 RNA Apt
[13] that can bind the extracellular domain of the prostate
speciﬁc membrane antigen (PSMA), and demonstrated
their capability for active binding and uptake by the
targeted cancer cells in vitro [14]. We also developed
 180nm docetaxel-encapsulated NP-Apt bioconjugates
using poly(D,L-lactide–co–glycolide)–block–poly(ethylene
glycol) (PLGA–b–PEG) copolymer that showed remark-
able antitumor efﬁcacy in vivo after a single intratumoral
administration to subcutaneous xenograft mouse models of
prostate cancer [15]. Although intratumoral drug delivery
is suitable for localized prostate cancer disease, patients
with advanced prostate cancer will require drugs to be
administered systemically for the treatment of disseminated
tumors [16]. Systemic delivery of targeted NPs presents
other challenges for developing an effective NP drug
delivery vehicle with desirable pharmacological properties
capable of extended circulation in blood and targeted drug
delivery.
Herein we report formulation strategies to control the
size of PLGA–b–PEG NPs during both synthesis and post-
synthesis processing. The ability to control NP size may be
broadly important to their use in various clinical applica-
tions, allowing for optimization of NP delivery vehicles for
systemic administration. For our technology, we chose one
NP-Apt bioconjugate formulation that has size and drug
loading characteristics that are potentially suitable for
systemic administration and tested its tumor targeting
efﬁciency and biodistribution when administered systemi-
cally to a xenograft mouse model of prostate cancer.
2. Materials and methods
2.1. Materials
Docetaxel and
14C-paclitaxel were purchased from Sigma-Aldrich
(St. Louis, MO). Poly(D,L-lactide–co–glycolide) (50/50) with terminal
carboxylate groups (PLGA, inherent viscosity 0.20dl/g in hexaﬂuoroiso-
propanol, MW  17kDa) was obtained from Absorbable Polymers
International (Pelham, AL, USA). NH2–PEG–COOH (MW 3400) was
purchased from Nektar Therapeutics (San Carlos, CA, USA). All reagents
were analytical grade or above and used as received, unless otherwise
stated. Molecular biology buffers were purchased from Boston BioPro-
ducts (Worcester, MA, USA). Tissue culture reagents and the LNCaP cell
line were obtained from American Type Culture Collection (Manassas,
VA, USA). RNA aptamer (sequence: 50-NH2-spacer-GGG/AGG/ACG/
AUG/CGG/AUC/AGC/CAU/GUU/UAC/GUC/ACU/CCU/UGU/CAA/
UCC/UCA/UCG/GCiT-30 with 20-ﬂuoro pyrimidines, a 50-amino
group attached by a hexaethyleneglycol spacer and a 30-inverted T cap)
was custom synthesized by RNA–TEC (Leuven, Belgium) at a purity
above 90%.
2.2. Methods
2.2.1. Synthesis of PLGA–b–PEG
Carboxylate-functionalized copolymer PLGA–b–PEG was synthesized
by the conjugation of COOH–PEG–NH2 to PLGA–COOH. PLGA–
COOH (5g, 0.28mmol) in methylene chloride (10mL) was converted to
PLGA–NHS with excess N-hydroxysuccinimide (NHS, 135mg, 1.1mmol)
in the presence of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC,
230mg, 1.2mmol). PLGA–NHS was precipitated with ethyl ether (5mL),
and repeatedly washed in an ice-cold mixture of ethyl ether and methanol
to remove residual NHS. After drying under vacuum, PLGA–NHS (1g,
0.059mmol) was dissolved in chloroform (4mL) followed by addition of
NH2–PEG–COOH (250mg, 0.074mmol) and N,N-diisopropylethylamine
(28mg, 0.22mmol). The co-polymer was precipitated with cold methanol
after 12h and washed with the same solvent (3 5mL) to remove
unreacted PEG. The resulting PLGA–PEG block co-polymer was dried
under vacuum and used for NP preparation without further treatment.
1H NMR (CDCl3 at 300Hz) d 5.2 (m, ((OCH(CH3)C(O)OCH2
C(O))n–(CH2CH2O)m), 4.8 (m, ((OCH(CH3)C(O)OCH2C(O))n–(CH2
CH2O)m), 3.7 (s, ((OCH(CH3)C(O)OCH2C(O))n–(CH2CH2O)m), 1.6 (d,
((OCH(CH3)C(O)OCH2C(O))n–(CH2CH2O)m).
2.2.2. Formulation of taxane drug-loaded PLGA–b–PEG NPs
The nanoprecipitation method was employed for the formation of
drug-encapsulated carboxylated PLGA–b–PEG NPs, similarly to pre-
viously described [15,17]. Brieﬂy, docetaxel (or
14C-paclitaxel) was
dissolved in various organic solvents that are miscible with water. Polymer
was likewise dissolved and mixed with the drug. NPs were formed by
adding the drug–polymer solution to water, a non-solvent. The resulting
NP suspension was allowed to stir uncovered for 6h at room temperature.
NPs were puriﬁed by centrifugation (10min, 10000g) or by ultraﬁltration
(15min, 3000g, Amicon Ultra, Ultracel membrane with 100,000 NMWL,
Millipore, Billerica, MA, USA). The PLGA–b–PEG NPs were re-
suspended, washed with water, and collected likewise.
Parameters controlling formation of the NPs were systematically varied
in this study. Generally, the starting formulation was as follows:
PLGA–b–PEG (10mg/mL) and docetaxel (0.1mg/mL) were dissolved in
acetonitrile. The mixture was added dropwise to a 2 volume of stirring
water. The NPs were produced with the nanoprecipitation method in four
solvents: N,N-dimethylformamide (DMF), acetone, acetonitrile, and
tetrahydrofuran (THF). The effects of the various solvents were assayed
on the overall size of the NPs. For each solvent, the ratio of solvent to
water was varied from 0.1 to 1 (using 10mg/mL polymer for each).
Further, a range of polymer concentrations in the organic phase from
5mg/mL to 50mg/mL was used for formation of NPs in a 2 volume of
water. The NPs were processed as above in triplicate, noting trends in
formulation parameters. In another study, NPs containing variable
amounts of docetaxel were synthesized by adjusting docetaxel drug
loading from 0% to 10% by weight of the added polymer, formulating the
NPs from 10mg/mL polymer in acetonitrile and a 2 volume of water.
NP post-formulation stability was studied for both the puriﬁcation and
bioconjugation steps and through the storage in solid-state after freeze-
drying. NPs were also ﬂash-frozen in liquid nitrogen prior to lyophiliza-
tion for freeze-drying.
2.2.3. Determination of particle sizes and polydispersities
The particle size distributions were measured by dynamic light
scattering (Brookhaven Instruments Corporation 90 plus particle sizer,
676nm laser) at 251C and at a scattering angle of 901 at a concentration of
approximately 1mg NP/mL water. The intensity-weighted mean value was
recorded as the average of three measurements.
2.2.4. Determination of drug content
NPs were dissolved in acetonitrile and measured by HPLC in triplicates
to determine docetaxel content. The Agilent 1100 HPLC (Palo Alto, CA)
was equipped with a UV detector and a reverse-phase pentaﬂuorophenyl
column (Curosil-PFP, 250 4.6mm, 5m, Phenomenex, Torrance, CA,
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USA) with a non-gradient mobile phase of water and acetonitrile (v/v 50/
50) at a constant ﬂow rate of 1mL/min. The docetaxel peak was measured
at a wavelength of 227nm and quantitatively determined by comparing
with a standard curve.
2.2.5. Conjugation of Apt to the PLGA–b–PEG–COOH NPs
PLGA–b–PEG NPs (10mg/mL) were suspended in water and were
incubated with EDC (400mM) and NHS (200mM) for 20min. NPs were
then repeatedly washed in DNase-, RNase-free water (3 15mL) followed
by ultraﬁltration. The NHS-activated NPs were reacted with 50-amino-
RNA Apt (1mg/mL). The resulting NP-Apt bioconjugates were washed
with ultrapure water (15mL) by ultraﬁltration, and the surface-bound
Apt were denatured at 901C and allowed to assume binding conforma-
tion during snap-cooling on ice. The NP suspensions were kept at 41C
until use.
NP-Apt bioconjugation was conﬁrmed on 10% TBE–urea PAGE. NPs
were incubated as above with (+EDC) and without ( EDC) the
crosslinker to conﬁrm covalent conjugation. Apt, NP, NP+Apt
(+EDC), NP+Apt ( EDC), washed NP+Apt (+EDC), and washed
NP+Apt ( EDC) were separated by PAGE. The molecular weight (MW)
DNA marker and free aptamer served as standards for a 57 base pair band
on the gel.
2.2.6. In vivo tumor targeting and biodistribution of NP-Apt bioconjugates
All animal studies were carried out under the supervision of MIT’s
Division of Comparative Medicine and in compliance with NIH’s
Principles of Laboratory Animal Care. Human xenograft prostate cancer
tumors were induced in 8-week old balb/c nude mice (Charles River
Laboratories, Wilmington, MA, USA). Mice were injected subcutaneously
in the right ﬂank with 3 10
6 LNCaP cells suspended in a 1:1 mixture of
media and matrigel (BD Biosciences, Franklin Lakes, NJ, USA). Prior to
use in tumor induction, LNCaP cells were cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum, 100units/mL penicillin G,
and 100mg/mL streptomycin.
Tumor targeting studies were carried out after the mice developed
 100mg tumors. Mice were divided into groups of four, minimizing
tumor size variations between groups. Mice were anesthesized by
intraperitoneal injection of avertin (200mg/kg body weight), and dosed
with NPs or NP-Apt bioconjugates by retro-orbital injection. The NPs
were traced by encapsulating
14C-paclitaxel and suspended in 200mL PBS
(1 ) prior to administration. Different groups were euthanized at 2, 6 or
24h, and 200mL of blood was drawn by cardiac puncture from each
mouse. The tumor, heart, lungs, liver, spleen and kidneys were harvested
from each animal. The
14C content of tissues was assayed in a Packard Tri-
Carb Scintillation Analyser (Downers Grove, IL, USA). The tissues were
solubilized in Solvable (Packard), and activity was counted in Hionic-
Fluor scintillation cocktail (PerkinElmer, Boston, MA, USA). The liver
from each mouse was homogenized due to its large size, and  100mg of
tissue was placed in a scintillation vial for analysis. The other organs were
placed directly in scintillation vials. Each organ was solubilized in 2mL
Solvable for  12h at 601C, and the resulting solution was de-colored with
200mL hydrogen peroxide for 1h at 601C. For the blood, 400mL Solvable
was added, and the vials were otherwise treated similarly to the tissues. To
determine 100% dose, vials of the formulated NPs were counted along
with the tissues. Data is presented as percent injected dose per gram of
tissue.
2.2.7. Statistical analysis
The statistical analysis of the samples was undertaken using a Student’s
t-test, and p-valueso0.05 were considered statistically signiﬁcant. All data
reported are means7standard deviations, unless otherwise noted.
3. Results and discussion
3.1. Synthesis of PLGA–b–PEG–COOH copolymer
We synthesized carboxyl-functionalized PLGA–b–PEG
copolymer by direct conjugation of PLGA–COOH with
NH2–PEG–COOH, both having ﬁxed block length, to
generate PLGA–b–PEG–COOH (Scheme 1). The carboxyl
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group in the copolymer is located at the terminal end of the
hydrophilic PEG block; therefore, upon NP formulation
the PEG should facilitate the presentation of the carboxyl
groups on the NP surface making them available for
surface chemistry. The RNA aptamers are synthesized with
50-amino groups that can be conjugated to the carboxyl
groups on the NP surface using carbodiimide coupling
chemistry (Scheme 1). After preparing the polymer, the
efﬁciency of the coupling reaction was determined by
1H
NMR, which revealed that approximately 83% of PLGA
was conjugated with the PEG segment.
3.2. Effects of varying formulation parameters to control
NP size
As a starting point for controlling the NP size distribu-
tion, we ﬁrst studied the effect of varying the type of
organic solvent used to solubilize the drug and polymer.
Previous studies have suggested that the miscibility of the
organic solvent in water can impact NP size for a given
solvent:water system [18,19]. Generally, the miscibility can
be quantitatively expressed by comparing the solubility
parameters (d) of both the solvent and water [20].A s
solvents become more miscible, the difference in solubility
parameters between the solvents (Dd) is minimized. We
chose to investigate the relationship of NP size and solvent
miscibility with water using four organic solvents and
observed a dependence of NP size on the solubility
parameters. As shown in Fig. 1, the sizes of PLGA–b–PEG
NPs and the water-miscibility of the four organic solvents
used in this study were generally correlated; an increase of
water miscibility (decrease in Dd, as indicated by the arrow
shown in Fig. 1) led to a decrease in the mean NP size, with
all other formulation parameters held constant. NPs
prepared in DMF, the most water miscible solvent tested,
resulted in the smallest particles, which is presumably due
to more efﬁcient solvent diffusion and polymer dispersion
into water.
In conjunction with our investigation of the effect of
solvent–water miscibility, we studied the effect of altering
the solvent:water ratio during NP formulation. When
solvent:water ratios were varied for a ﬁxed polymer
concentration (10mg/mL) as shown in Fig. 1A, no clear
correlation of particle size with solvent-to-water ratio was
observed. Most of the NP sizes remained relatively
unchanged when the ratio was in a range of 0.1–0.5. In
acetone, for example, NP sizes increased from 115.375.1
to 120.976.9nm as the Vsolvent/Vwater ratio increased from
0.1 to 0.5, respectively (mean7SD, n ¼ 3 for each
formulation; p40:05). For THF, the size remained
consistent as the ratio was varied from 0.1 to 0.5, with
respective sizes of 13070.5 and 129715.5nm. At the
solvent:water ratio of 1, a large increase in particle size was
observed presumably due to poor phase separation—NPs
formulated in acetonitrile and THF were sized greater than
200nm (po0:05, comparing sizes for ratio of 1 vs. 0.5).
When polymer concentrations were varied during NP
formulation at a ﬁxed solvent:water ratio (Fig. 1B), we
observed a trend of increasing NP size with increasing
polymer concentration. For example, NP sizes increased
from 69.0 to 165.0nm in DMF as the polymer concentra-
tion increased 10 times from 5 to 50mg/mL. Similar trends
were observed in all other solvents investigated. Interest-
ingly, interpreting the data in terms of changes in
volumetric size showed linear agreement between size and
polymer concentration. The R
2 values for the plot of mean
NP volume and polymer concentration (Fig. 2) were 0.997,
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0.985, 0.998, and 0.997 for DMF, acetone, THF, and
acetonitrile, respectively. For our polymer system, using
the linear correlation of the NP volumetric size and
polymer concentration allows for formulation of NP with
predeﬁned, desired sizes.
3.3. NP polydispersity at different drug loadings
For our PLGA–b–PEG system, we studied the effect
of docetaxel loading on resulting NP size distributions,
comparing NPs loaded with 1%, 5% and 10% docetaxel.
For a given NP formulation (150nm NPs), the polydis-
persity of the particle preparations increased with docetaxel
concentration as follows: from 0.154 for the 1% loading to
0.203 for the 5% loading and 0.212 for the 10% loading.
The size distribution of the NPs exhibited a biphasic trend
with a smaller diameter particle distribution accompanied
by a distribution of larger diameter particles (Fig. 3). The
distribution corresponding to the smaller particles did not
shift with the increase of drug concentration. The larger
diameter locus of the two size distributions shifted higher
as the drug loading increased (the size increasing from
 300nm to  1200nm, Fig. 3). Since the only difference
between these formulations is the amount of drug loading,
a signiﬁcant amount of the NPs formed may be due to
aggregation of unencapsulated docetaxel, due to its poor
water solubility.
Previous studies have shown that in order to release
taxane drugs at a sustainable rate from PLGA NPs, the
drug loading concentrations should be limited [21],
especially in the case of pegylated NPs [22]. Some studies
have suggested that drug loading can be increased [23] or
that release can be sustained [24] by using high molecular
weight PLGA. In our polymer system, we found that drug
loadings of 1% minimized NP polydispersity, and thus
these NPs may behave most predictably in vivo.
3.4. Control of NP size during post-formulation treatment
NPs formed by nanoprecipitation generally do not
require surfactant; however, the lack of surfactant can
cause NP aggregation after formulation. High-speed
centrifugation, for example, can substantially increase
particle size due to aggregation upon pelleting. After NPs
( 80nm) were centrifuged at 10,000g for 10min, an
increase in diameter of approximately 20–30% was
observed for each of the centrifugation steps (Fig. 4A).
However, the mechanical force that causes aggregation
can be substantially avoided by low-speed ultraﬁltration
(Fig. 4A). Use of a commercially available centrifuge
ﬁltration device reproducibly controls the particle size
during multiple washing steps.
For translation to clinical use of any biodegradable
formulation, stability upon storage is a concern. Freeze-
drying the NPs and storing frozen in solid state is a
common approach, and sugars like sucrose can act as a
lyoprotectant during the process [25,26]. Addition of 10%
sucrose to an aqueous NP suspension (10mg/mL) allows
recovery of NPs of very similar size as originally
formulated (Fig. 4B). Without sucrose as a lyoprotectant,
the NPs aggregated to a few micrometers in size and were
not useful upon reconstitution for in vivo systemic delivery
(Fig. 4B). Further investigation is necessary to determine
whether other properties of the NPs, such as drug release
proﬁle, are unchanged.
3.5. Conjugation of Apt to NP
PAGE was utilized to examine the conjugation of the
NPs to Apts, and to demonstrate successful removal of
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unconjugated Apts after the reaction. The mixing of Apt
and NP without the addition of the coupling agent
( EDC, Fig. 5) did not show any band of conjugated
Apt, indicating a lack of non-speciﬁc interaction between
the Apt and NP. Conjugation with the addition of EDC
(+EDC, Fig. 5) leads to RNA bands consistent with RNA
covalently bound to the NPs and unable to run on the gel,
both before and after washing. After repetitive washing
by ultraﬁltration, the unconjugated Apt was no longer
detectable (Fig. 5).
3.6. In vivo tumor targeting and biodistribution of NP-Apt
bioconjugates
As a result of our investigations of formulation
parameters and their effects on NP size, an optimal NP
formulation in terms of size and drug loading was chosen
for in vivo study. For the study,
14C-paclitaxel (serving
as a tracing agent) was encapsulated at a drug loading of
1% into the PLGA–b–PEG NPs. Paclitaxel is a taxane
drug related to docetaxel and is available commercially
as a radiochemical. The resulting NPs were sized at
156.873.9nm. After bioconjugation with the aptamers,
the ﬁnal size of the NP-Apt bioconjugates was measured
to be 188.174.0nm. At all three time-points, the
14C-
paclitaxel dose recovered in the tumor was higher for the
NP-Apt targeted groups compared to the control NP
groups (Fig. 6). The values in % injected dose/g of tissue at
2, 6, and 24h for the NP-Apt group were 1.4970.92,
1.9871.72, and 0.8370.21, respectively (mean7SD,
n ¼ 4). For the NP control group, the respective values
at 2, 6, and 24h were 1.1070.20, 0.9670.44, and
0.2270.07. At the 24h endpoint of the study, the level in
the tumor was 3.77-fold higher for the NP-Apt group
(p ¼ 0:002, n ¼ 4). At the 2 and 6h time-points, the level of
NP-Apt in the tumor was 1.35 and 2.06-fold higher than
the control, respectively, but this difference was not
statistically signiﬁcant. Interestingly in both 2 and 6h
groups the intra-tumoral concentrations of the NP-Apt
increased as compared to the NP control, while the levels in
most other tissues decreased in parallel to less NPs in
circulation. We postulated that the concentration of the
recovered drug in the tumor over time shows both
the enhanced permeation and retention effect [27] and the
effect of targeting. The ability of the NP-Apt bioconjugates
to maintain a signiﬁcantly higher concentration in the
tumor at 24h is possibly due to uptake by the targeted
LNCaP cells, while the NP group without targeting ligand
diffused away from the tumor over time in the absence of
cell uptake. Similar strong binding of the NP-Apt
bioconjugates to LNCaP cells was observed in vitro [14].
Additionally, the concentration in the tumor for both
groups may decline from the 6 and 24h time-points due to
the burst effect of the NPs, which can release a large
percentage of the drug during this time [17]. Drug released
at the tumor site, if not internalized by the cells, can diffuse
away or be clear from the site.
Biodistribution patterns to the heart, lungs, and kidneys
did not show substantial accumulation in either group and
were not signiﬁcantly different (Fig. 7). The uptake by the
RES, including the spleen and liver, was observed to be
higher for the NP-Apt bioconjugates as compared to the
control NPs. The outer PEG layer, while providing an
excellent stealth shield for the NP group, was modiﬁed in
the NP-Apt group by surface bioconjugation. Apts are not
considered immunogenic, and thus the likely cause of the
observed RES uptake was this disruption of the PEG
shield. While not a focus of this study, the Apt surface
coating and length of PEG chains employed in the NP can
be varied perhaps to improve on this outcome. Further, the
bioconjugation resulted in a moderate increase in
mean particle size compared to the NP group. The
increased size can partially explain the increased uptake
in the spleen [9].
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4. Conclusions
We studied the effect of solvent type, polymer concen-
tration, and solvent:water ratio on the size of pegylated
PLGA NPs formulated with the nanoprecipitation method,
and for the ﬁrst time report a linear correlation between
polymer concentrations and volumetric sizes of the
resulting NPs. This observation was conﬁrmed after
evaluating four distinct solvents and may extend to other
polymer systems, broadly enabling the reproducible tuning
of polymeric NP sizes during their formulation.
We next conjugated the resulting pegylated PLGA NPs
to the A10 aptamer and demonstrated enhanced NP
delivery to prostate tumors as compared to equivalent
non-targeted NPs. This is the ﬁrst report of a tumor speciﬁc
systemic targeting of a NP-Apt bioconjugate system in vivo
and may result in the development of therapeutically
effective vehicles for disseminated prostate cancer for
which the current therapies are largely ineffective.
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